UCB (ENXTBR:UCB) - Prezzo delle azioni, notizie e analisi

UCB Panoramica delle azioni

UCB SA, azienda biofarmaceutica, sviluppa prodotti e soluzioni per le persone affette da malattie neurologiche e immunologiche in tutto il mondo. Maggiori dettagli

UCB analisi fondamentale
Punteggio fiocco di neve
Valutazione	2/6
Crescita futura	4/6
Prestazioni passate	1/6
Salute finanziaria	4/6
Dividendi	0/6

Premi

Negoziato a 67.6% al di sotto della nostra stima del suo valore equo

Si prevede che gli utili cresceranno del 35.94% all'anno

Analisi del rischio

I margini di profitto (4.4%) sono inferiori rispetto allo scorso anno (6.5%)

UCB SA Concorrenti

Financière de Tubize

ENXTBR:TUB

€5.8b

Jiangsu Hengrui Medicine

SHSE:600276

CN¥319.1b

Otsuka Holdings

TSE:4578

JP¥4.8t

Takeda Pharmaceutical

TSE:4502

JP¥6.5t

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per UCB
Prezzi storici delle azioni
Prezzo attuale dell'azione	€174.15
Massimo di 52 settimane	€186.70
Minimo di 52 settimane	€67.08
Beta	0.32
1Variazione di 1 mese	1.84%
Variazione a 3 mesi	8.20%
Variazione di 1 anno	151.66%
3Variazione a 3 anni	73.37%
Variazione a 5 anni	137.39%
Variazione dall'IPO	56,972.91%

Notizie e aggiornamenti recenti

Why We're Not Concerned About UCB SA's (EBR:UCB) Share Price

Oct 22

These 4 Measures Indicate That UCB (EBR:UCB) Is Using Debt Reasonably Well

Sep 10

Recent updates

Why We're Not Concerned About UCB SA's (EBR:UCB) Share Price

Oct 22

These 4 Measures Indicate That UCB (EBR:UCB) Is Using Debt Reasonably Well

Sep 10

Analysts Have Made A Financial Statement On UCB SA's (EBR:UCB) Half-Yearly Report

Jul 28

Investors Still Waiting For A Pull Back In UCB SA (EBR:UCB)

Jul 15

Shareholders Will Probably Not Have Any Issues With UCB SA's (EBR:UCB) CEO Compensation

Apr 19

UCB SA Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Jul 31

Is UCB (EBR:UCB) A Risky Investment?

Jun 21

UCB SA's (EBR:UCB) Intrinsic Value Is Potentially 96% Above Its Share Price

May 13

Rendimenti per gli azionisti

	UCB	BE Pharmaceuticals	BE Mercato
7D	-2.2%	-3.0%	-1.6%
1Y	151.7%	4.3%	2.0%

Ritorno vs Industria: UCB ha superato il Belgian Pharmaceuticals che ha restituito 4.3 % nell'ultimo anno.

Rendimento vs Mercato: UCB ha superato il mercato Belgian che ha restituito 2 % nell'ultimo anno.

Volatilità dei prezzi

Is UCB's price volatile compared to industry and market?
UCB volatility
UCB Average Weekly Movement	3.6%
Pharmaceuticals Industry Average Movement	5.3%
Market Average Movement	3.3%
10% most volatile stocks in BE Market	6.3%
10% least volatile stocks in BE Market	2.1%

Prezzo delle azioni stabile: UCB non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi.

Volatilità nel tempo: La volatilità settimanale ( 4% ) di UCB è rimasta stabile nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
1925	9,000	Jean-Christophe Tellier	www.ucb.com

UCB SA, azienda biofarmaceutica, sviluppa prodotti e soluzioni per le persone affette da malattie neurologiche e immunologiche in tutto il mondo. I prodotti principali dell'azienda includono Cimzia per le malattie infiammatorie TNF mediate, oltre che per la spondilite anchilosante, la spondiloartrite assiale, il morbo di Crohn, la spondiloartrite assiale non radiologica, la psoriasi a placche, l'artrite psoriasica e l'artrite reumatoide; Vimpat, Keppra e Briviact per l'epilessia; Neupro per il morbo di Parkinson e la sindrome delle gambe senza riposo; Nayzilam, un trattamento di salvataggio in spray nasale per i gruppi di crisi epilettiche; Zyrtec e Xyzal per le allergie. L'azienda offre anche Evenity per il trattamento dell'osteoporosi nelle donne in postmenopausa; Bimzelx per il trattamento della psoriasi a placche, dell'artrite psoriasica e della spondiloartrite assiale; e Fintepla per il trattamento della sindrome di Dravet.

UCB SA Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di UCB con la sua capitalizzazione di mercato?
UCB statistiche fondamentali
Capitalizzazione di mercato	€32.23b
Guadagni(TTM)	€240.00m
Ricavi(TTM)	€5.45b

137.7x

Rapporto P/E

6.1x

Rapporto P/S

UCB è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
UCB Conto economico (TTM)
Ricavi	€5.45b
Costo del fatturato	€1.76b
Profitto lordo	€3.70b
Altre spese	€3.46b
Guadagni	€240.00m

Ultimi guadagni dichiarati

Jun 30, 2024

Prossima data di guadagno

Feb 27, 2025

Utile per azione (EPS)	1.27
Margine lordo	67.80%
Margine di profitto netto	4.40%
Rapporto debito/patrimonio netto	31.8%

Come si è comportato UCB nel lungo periodo?

Vedi performance storica e confronto

Dividendi

0.8%

Rendimento attuale del dividendo

108%

Rapporto di remunerazione

UCB Panoramica delle azioni

Premi

Analisi del rischio

UCB SA Concorrenti

ENXTBR:TUB

€5.8b

SHSE:600276

CN¥319.1b

TSE:4578

JP¥4.8t

TSE:4502

JP¥6.5t

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

UCB SA Receives U.S. FDA Approval for Bimzelx (Bimekizumab-Bkzx) as the First Il-17A and Il-17F Inhibitor for Adults with Moderate-Severe Hidradenitis Suppurativa

Ucb Announces New Bimzelx (Bimekizumab-Bkzx) Data at Acr Convergence 2024

Why We're Not Concerned About UCB SA's (EBR:UCB) Share Price

UCB Announces Head-To-Head Study Evaluating Bimekizumab (bimekizumab) versus SKYRIZI® (risankizumab) in Active Psoriatic Arthritis

UCB Announces Late-Breaking Two-Year Data for BIMZELX (bimekizumab-bkzx) in Moderate-to-Severe Hidradenitis Suppurativa at EADV 2024

These 4 Measures Indicate That UCB (EBR:UCB) Is Using Debt Reasonably Well

Recent updates

UCB SA Receives U.S. FDA Approval for Bimzelx (Bimekizumab-Bkzx) as the First Il-17A and Il-17F Inhibitor for Adults with Moderate-Severe Hidradenitis Suppurativa

Ucb Announces New Bimzelx (Bimekizumab-Bkzx) Data at Acr Convergence 2024

Why We're Not Concerned About UCB SA's (EBR:UCB) Share Price

UCB Announces Head-To-Head Study Evaluating Bimekizumab (bimekizumab) versus SKYRIZI® (risankizumab) in Active Psoriatic Arthritis

UCB Announces Late-Breaking Two-Year Data for BIMZELX (bimekizumab-bkzx) in Moderate-to-Severe Hidradenitis Suppurativa at EADV 2024

These 4 Measures Indicate That UCB (EBR:UCB) Is Using Debt Reasonably Well

Consensus EPS estimates increase by 14%

Price target increased by 8.5% to €153

Analysts Have Made A Financial Statement On UCB SA's (EBR:UCB) Half-Yearly Report

First half 2024 earnings released: EPS: €1.10 (vs €1.64 in 1H 2023)

Investors Still Waiting For A Pull Back In UCB SA (EBR:UCB)

Price target increased by 7.2% to €135

UCB Announces New CIMZIA® Data for Women Living with Chronic Rheumatic Diseases Throughout Pregnancy, and for People Living with Ra and High Rheumatoid Factor Levels

UCB SA, Annual General Meeting, Apr 24, 2025

Insufficient new directors

UCB SA to Report First Half, 2024 Results on Jul 25, 2024

Dividend of €0.95 announced

Shareholders Will Probably Not Have Any Issues With UCB SA's (EBR:UCB) CEO Compensation

Consensus EPS estimates increase by 18%

UCB Announces FDA Accepts Supplemental Biologics License Applications for Bimzelx

Is UCB (EBR:UCB) A Risky Investment?

UCB Announces 48-Week Phase 3 Analyses of Pooled Phase 3 Data from the BE HEARD I and BE HEARD II Studies

Price target increased by 9.4% to €111

Consensus EPS estimates fall by 14%

Earnings Tell The Story For UCB SA (EBR:UCB) As Its Stock Soars 26%

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

UCB SA's (EBR:UCB) P/E Is On The Mark

UCB Presents New Data About the Real-World Experience of FINTEPLA® (Fenfluramine) and Rare Epilepsy Syndromes At 2023 American Epilepsy Society (AES) Annual Meeting

UCB SA Announces U.S. Availability of BIMZELX for the Treatment of Adults with Moderate-To-Severe Plaque Psoriasis

UCB to Present Post Hoc Analysis of the EXXELERATE Trial Evaluating the Efficacy of CIMZIA®? (Certolizumab Pegol) and Adalimumab in Patients with Rheumatoid Arthritis and High Rheumatoid Factor

UCB (EBR:UCB) Takes On Some Risk With Its Use Of Debt

UCB Presents Latest Data from Generalized Myasthenia Gravis Portfolio

UCB SA Announces Publication of NAYZILAM® (midazolam) Results in 'Epilepsy & Behavior' Examining the Impact of Dose on Return to Full Baseline Function (RTFBF) for People with Seizure Clusters

UCB Announces U.S. FDA Approves BIMZELX (Bimekizumab-Bkzx) for the Treatment of Adults with Moderate-To-Severe Plaque Psoriasis

UCB Announces U.S. FDA approval of ZILBRYSQ® (zilucoplan) for the Treatment of Adults with Generalized Myasthenia Gravis

UCB Reinforces Commitment to Advancing Care in Hidradenitis Suppurativa with Six Abstracts at SHSA 2023

UCB Announces Phase 3 Data Analysis Presented at EADV 2023 Showed Bimekizumab Achieved High Thresholds of Clinical Response in Hidradenitis Suppurativa

Is UCB (EBR:UCB) Using Too Much Debt?

UCB SA to Report Fiscal Year 2023 Results on Feb 21, 2024

First half 2023 earnings released: EPS: €1.64 (vs €2.10 in 1H 2022)

Ucb Announces That Rystiggo Is Commercially Available for the Treatment of Adult Patients in the U.S. with Generalized Myasthenia Gravis (Gmg) Who Are Anti-Acetylcholine Receptor (Achr) or Anti-Muscle-Specific Tyrosine Kinase (Musk) Antibody Positive

UCB Announces Resignation of Head of Neurology Solutions Charl Van Zyl

Are Investors Undervaluing UCB SA (EBR:UCB) By 48%?

Upcoming dividend of €0.93 per share at 1.5% yield

UCB's (EBR:UCB) Upcoming Dividend Will Be Larger Than Last Year's

Does UCB (EBR:UCB) Have A Healthy Balance Sheet?

Consensus EPS estimates fall by 17%

Consensus EPS estimates fall by 16%

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

UCB Announces Annals of the Rheumatic Diseases Publishes Results from Two Bimekizumab Phase 3 Studies in Axial Spondyloarthritis

UCB SA to Report Fiscal Year 2022 Results on Feb 22, 2023

UCB Announces Rozanolixizumab BLA for the Treatment of Generalized Myasthenia Gravis Filed with U.S. FDA and Designated for Priority Review

UCB Announces Positive Phase 3 Studies for Bimekizumab in Hidradenitis Suppurativa

Here's Why UCB (EBR:UCB) Can Manage Its Debt Responsibly

UCB SA to Present Data At the American Epilepsy Society 76Th Annual Meeting 2022 Supporting A Decades-Long Commitment to Transforming Epilepsy Care

UCB Announces the Publication of Long-Term Open-Label Extension (OLE) Study Results of FINTEPLA® (Fenfluramine) CIV in Epilepsia

UCB Announces U.S. FDA Acceptance of New Drug Application and EMA MAA Validation for Zilucoplan for the Treatment of Generalized Myasthenia Gravis in Adult Patients

UCB Announces the First Presentation of Long-Term, 52-Week Data from Three Phase 3 Studies Evaluating the Efficacy and Safety of Bimekizumab in Adults with Active Psoriatic Arthritis

UCB Announces New Three-Year Results from the BE BRIGHT Open-Label Extension Study